01Apr/21
The U.S. FDA Approved the First BCMA-targeted CAR-T Therapy
Bristol-Myers Squibb (BMS) and bluebird bio announced that the Food and Drug Administration (FDA) has approved the marketing of Abecma (idecabtagene vicleucel), a chimeric antigen receptor T (CAR-T) cell immunotherapy targeting BRead More…
